X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse JUBILANT LIFE SCIENCES with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 JUBILANT LIFE SCIENCES   MYLAN
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
MYLAN
Dec-14
JUBILANT LIFE SCIENCES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1873,867-   
Low Rs652,725-   
Sales per share (Unadj.) Rs364.31,324.0-  
Earnings per share (Unadj.) Rs6.8159.5-  
Cash flow per share (Unadj.) Rs24.5256.7-  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %2.40-  
Book value per share (Unadj.) Rs164.9658.1-  
Shares outstanding (eoy) m159.28378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x0.32.5 13.9%   
Avg P/E ratio x18.420.7 89.0%  
P/CF ratio (eoy) x5.112.8 40.0%  
Price / Book Value ratio x0.85.0 15.2%  
Dividend payout %43.80-   
Avg Mkt Cap Rs m20,0611,247,263 1.6%   
No. of employees `0006.225.0 24.7%   
Total wages/salary Rs m11,0520-   
Avg. sales/employee Rs Th9,383.020,038.0 46.8%   
Avg. wages/employee Rs Th1,786.90-   
Avg. net profit/employee Rs Th176.32,413.9 7.3%   
INCOME DATA
Net Sales Rs m58,034500,951 11.6%  
Other income Rs m191-2,920 -6.5%   
Total revenues Rs m58,224498,031 11.7%   
Gross profit Rs m5,786124,589 4.6%  
Depreciation Rs m2,81236,793 7.6%   
Interest Rs m3,23721,608 15.0%   
Profit before tax Rs m-7263,268 -0.1%   
Minority Interest Rs m-286-260 110.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6962,660 26.2%   
Profit after tax Rs m1,09060,348 1.8%  
Gross profit margin %10.024.9 40.1%  
Effective tax rate %-965.94.2 -22,969.1%   
Net profit margin %1.912.0 15.6%  
BALANCE SHEET DATA
Current assets Rs m29,280440,402 6.6%   
Current liabilities Rs m38,912344,306 11.3%   
Net working cap to sales %-16.619.2 -86.5%  
Current ratio x0.81.3 58.8%  
Inventory Days Days8478 108.1%  
Debtors Days Days51107 47.2%  
Net fixed assets Rs m55,712115,894 48.1%   
Share capital Rs m15517,715 0.9%   
"Free" reserves Rs m20,9680-   
Net worth Rs m26,265249,022 10.5%   
Long term debt Rs m17,169372,014 4.6%   
Total assets Rs m88,6061,003,037 8.8%  
Interest coverage x1.03.9 24.9%   
Debt to equity ratio x0.71.5 43.8%  
Sales to assets ratio x0.70.5 131.1%   
Return on assets %4.98.2 59.8%  
Return on equity %4.224.2 17.1%  
Return on capital %11.613.6 84.9%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Net fx Rs m10,2550-   
CASH FLOW
From Operations Rs m8,02665,850 12.2%  
From Investments Rs m-1,744-51,931 3.4%  
From Financial Activity Rs m-4,447-17,352 25.6%  
Net Cashflow Rs m1,834-3,433 -53.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare JUBILANT LIFE SCIENCES With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare JUBILANT LIFE SCIENCES With: DR. REDDYS LAB  PIRAMAL ENTERPRISES  FULFORD INDIA  PANACEA BIOTECH  TORRENT PHARMA  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Feb 23, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - J.B.CHEMICALS COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS